Summary of statistical tests used
| Figure | Experiment | n | Type of test | Statistical analysis |
|---|---|---|---|---|
| Figure 1F | Aβ toxicity assay, cortical culture, nTg vs 14-3-3θ | nTg = 6; 14-3-3θ = 7 | Two-way ANOVA | Genotype: F(1,33) = 20.28; p < 0.0001 Ab dose: F(2,33) = 38.67; p < 0.0001 Interaction: F(2,33) = 15.40, p < 0.0001 Sidak’s: nTg vs 14-3-3θ at 0 μm p = 0.2173, at 1 μm p = 0.0012, at 5 μm p < 0.0001 |
| Figure 1G | Aβ toxicity assay, hippocampal culture, nTg vs 14-3-3θ | nTg = 6–7; 14-3-3θ = 7 | Two-way ANOVA | Genotype: F(1,35) = 5.801, p = 0.0214 Ab dose: F(2,35) = 27.00, p < 0.0001 Interaction: F(2,35) = 1.626, p = 0.2112 Sidak’s: nTg vs 14-3-3θ at 0 μm p = 0.0506, at 1 μm p > 0.9999, at 5 μm p = 0.3181 |
| Figure 1H | Aβ toxicity assay, cortical culture, nTg vs difopein | n = 4 | Two-way ANOVA | Genotype: F(1,18) = 25.85, p < 0.0001 Ab dose: F(2,18) = 42.68; p < 0.0001 Interaction: F(2,18) = 9.481, p =0.0015 Sidak’s: nTg vs 14-3-3θ at 0 μm p = 0.9551, at 1 μm p = 0.0044, at 5 μm p < 0.0001 |
| Figure 1I | Aβ toxicity assay, hippocampal culture, nTg vs difopein | n = 4 | Two-way ANOVA | Genotype: F(1,18) = 3.952, p = 0.0622 Ab dose: F(2,18) = 16.47, p < 0.0001 Interaction: F(2,18) = 0.6126, p = 0.5529 Sidak’s: nTg vs 14-3-3θ at 0 μm p = 0.9639, at 1 μm p = 0.1763, at 5 μm p = 0.6845 |
| Figure 2E | J20, 2 MPI, open field distance traveled | nTg/GFp = 10; nTg/14-3-3θ = 10; J20/GFp = 9; J20/14-3-3θ = 8 | Two-way ANOVA | Interaction: F(1,33) = 3.746, p = 0.0615 APP genotype factor: F(1,33) = 45.57, p < 0.001 AAV injection type factor: F(1,33) = 5.910, p = 0.0207 Tukey’s: nTg/GFP vs J20/GFP, p = 0.0081; nTg/14-3-3θ vs J20/14-3-3θ, p < 0.0001; J20/GFP vs J20/14-3-3θ, p = 0.0279; nTg/GFP vs J20/GFP, p = 0.0081; nTg/14-3-3θ vs J20/GFP, p = 0.0184 |
| Figure 2F | J20, 2 MPI, EPM percent time in open arm | nTg/GFp = 10; nTg/14-3-3θ = 10; J20/GFp = 9; J20/14-3-3θ = 8 | Two-way ANOVA | Interaction: F(1,33) = 0.8565, p = 0.3614 APP genotype factor: F(1,33) = 2.451, p = 0.1270 AAV injection type factor: F(1,33) = 0.8338, p = 0.3678 |
| Figure 2G | J20, 2 MPI, MWM latency to platform | nTg/GFp = 10; nTg/14-3-3θ = 10; J20/GFp = 9; J20/14-3-3θ = 7 | Three-way ANOVA | Time: F(4,85) = 16.33, p < 0.0001 Genotype: F(1,85) = 105.0, p < 0.0001 Virus: F(1,79) = 2.544, p = 0.1147 Time × genotype: F(4,85) = 3.840, p = 0.0064 Time × virus: F(4,79) = 0.7289, p = 0.5749 Genotype × virus: F(1,79) = 2.266, p = 0.1362 Time × genotype × virus: F(4,79) = 2.713, p = 0.0357 Tukey’s: day 5 comparisons: nTg/GFP vs nTg/14-3-3θ, p > 0.9999; nTg/GFP vs J20/GFP, p = 0.1287; J20/GFP vs J20/14-3-3θ, p = 0.5494; nTg/GFP vs J20/14-3-3θ, p < 0.0001; nTg/14-3-3θ vs J20/GFP, p = 0.0794; ntg/14-3-3θ vs J20/14-3-3θ p < 0.0001 |
| Figure 2H | J20, 2 MPI, MWM probe trial, time in target quadrant | nTg/GFp = 10; nTg/14-3-3θ = 10; J20/GFp = 9; J20/14-3-3θ = 7 | Two-way ANOVA | Interaction: F(1,32) = 4.622, p = 0.0392 APP genotype factor: F(1,32) = 3.675, p = 0.0642 AAV injection type factor: F(1,32) = 3.170, p = 0.5773 Tukey’s: nTg/14-3-3θ vs J20/14-3-3θ, p = 0.0426 |
| Figure 2I | AAV-injected J20 survival curve | nTg/GFp = 7; nTg/14-3-3θ = 10; J20/GFp = 10; J20/14-3-3θ = 11 | log-rank/Mantel–Cox | p = 0.201 |
| Figure 2J | J20, 6 MPI, open field distance traveled | nTg/GFp = 9; nTg/14-3-3θ = 10; J20/GFp = 7; J20/14-3-3θ = 5 | Two-way ANOVA | Interaction: F(1,27) = 0.7530, p = 0.3932 APP genotype factor: F(1,27) = 40.84, p < 0.0001 AAV injection type factor: F(1,27) = 0.1557, p = 0.9016 Tukey’s: nTg/GFP vs J20/GFP, p < 0.0001; nTg/14-3-3θ vs J20/14-3-3θ, p = 0.0044; nTg/GFP vs J20/14-3-3θ, p = 0.0015; nTg/14-3-3θ vs J20/GFP, p = 0.0002 |
| Figure 2K | J20, 6 MPI, EPM percent time in open arm | nTg/GFp = 9; nTg/14-3-3θ = 10; J20/GFp = 7; J20/14-3-3θ = 5 | Two-way ANOVA | Interaction: F(1,27) = 0.3644, p = 0.5511 APP genotype factor: F(1,27) = 4.821, p = 0.0369 AAV injection type factor: F(1,27) = 0.1706, p = 0.6828 |
| Figure 2L | J20, 6 MPI, MWM latency to platform | nTg/GFp = 9; nTg/14-3-3θ = 10; J20/GFp = 7; J20/14-3-3θ = 5 | Three-way ANOVA | Time: F(4,75) = 12.86, p < 0.0001 Genotype: F(1,75) = 46.69, p < 0.0001 Virus: F(1,60) = 6.839, p = 0.0113 Time × genotype: F(4,75) = 0.5912, p = 0.6700 Time × virus: F(4,60) = 0.6958, p = 0.5978 Genotype × virus: F(1,60) = 0.3838, p = 0.5379 Time × genotype × virus: F(4,60) = 0.2333, p = 0.9186 Tukey’s: day 5 comparisons: nTg/GFP vs nTg/14-3-3θ, p > 0.9999; nTg/GFP vs J20/GFP, p = 0.1562; J20/GFP vs J20/14-3-3θ, p > 0.9999; nTg/GFP vs J20/14-3-3θ, p = 0.3373; nTg/14-3-3θ vs J20/GFP, p = 0.3086; ntg/14-3-3θ vs J20/14-3-3θ p = 0.5425 |
| Figure 3C | APP KI, 8–9 months, open field distance traveled | nTg = 10; APP KI = 16; APP KI/14-3-3θ = 11 | One-way ANOVA | F(2,34) = 0.9122, p = 0.4112 |
| Figure 3D | APP KI, 8–9 months, EPM percent time in open arm | nTg = 10; APP KI = 15; APP KI/14-3-3θ = 9 | One-way ANOVA | F(2,31) = 11.17, p = 0.0002 Tukey’s: APP KI/14-3-3θ vs APP KI, p = 0.0001; APP KI/14-3-3θ- vs nTg, 0.0175 |
| Figure 3E | APP KI, 8–9 months, passive avoidance latency to dark side, D2 | nTg = 10; APP KI = 14; APP KI/14-3-3θ = 8 | One-way ANOVA | F(2,29) = 0.1705, p = 0.8441 |
| Figure 4A | J20 hippocampal Aβ plaque load | J20/GFp = 6; J20/14-3-3θ = 5 | Unpaired, two-tailed, t test | t = 0.09254, df = 9; p = 0.9238 |
| Figure 4B | APP KI hippocampal Aβ plaque load | APP KI = 16; APP KI/14-3-3θ = 10 | Unpaired, two-tailed, t test | t = 1.038, df = 24; p = 0.3084 |
| Figure 4C | APP KI cortical Aβ plaque load | APP KI = 15; APP KI/14-3-3θ = 10 | Unpaired, two-tailed, t test | t = 1.475, df = 23; p = 0.1538 |
| Figure 5A | J20 hippocampal synapsin immunoreactivity | nTg/GFp = 8; nTg/14-3-3θ = 9; J20/GFp = 5; J20/14-3-3θ = 5 | Two-way ANOVA | Interaction: F(1,23) = 0.3085, p = 0.5839 APP genotype factor: F(1,23) = 0.1737, p = 0.6807 AAV injection type factor: F(1,23) = 0.7492, p = 0.3957 |
| Figure 5B | APP KI hippocampal synapsin immunoreactivity | nTg = 9; APP KI = 16; APP KI/14-3-3θ = 9 | One-way ANOVA | F(2,31) = 0.4169, p = 0.6627 |